BMS-817 (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if Nivolumab and Ipilimumab will work for treating lung cancer with high tumor mutation burden.
Non-small cell lung cancer (NSCLC)
Who Can Participate in the Study?
Adults who have lung cancer (first-line non-small cell lung cancer) with high tumor mutation burden (TMB)
What is Involved?
If you choose to join this study, you will:
- Get nivolumab 240 mg every 2 weeks and ipilimumab at 1 mg/kg every 6 weeks as long as you are getting better